QuidelOrtho Corporation logo QDEL - QuidelOrtho Corporation

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 0
BUY 6
HOLD 7
SELL 2
STRONG
SELL 0
| PRICE TARGET: $12.25 DETAILS
HIGH: $12.50
LOW: $12.00
MEDIAN: $12.25
CONSENSUS: $12.25
DOWNSIDE: 8.45%

Stock News

Faster Answers, Better Decisions: ADLM 2026 Highlights

Faster Answers, Better Decisions: ADLM 2026 Highlights

SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference. Hosted by Stephanie Kleewein, the special episode showcases three presentations addressing some of healthcare's most pressing challenges: delivering faster molecular diagnostic results, improving antibiotic stewardship and accelerating cardiovascular assessment.

Aug 27, 2026 05:12 AM • prnewswire.com
QuidelOrtho Reports Second Quarter 2026 Financial Results

QuidelOrtho Reports Second Quarter 2026 Financial Results

― Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ―  ― Excluding China, total revenue grew 6% both as reported and in constant currency ― ― Company updates full-year 2026 financial guidance ― SAN DIEGO, Aug. 6, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, today announced financial results for the second quarter ended June 28, 2026. Key Second Quarter 2026 Results: (all comparisons are to the prior year period) Total revenue was $631 million, an increase of 3% as reported and 2% in constant currency.

Aug 06, 2026 12:05 PM • prnewswire.com
QuidelOrtho to Report Second Quarter 2026 Financial Results

QuidelOrtho to Report Second Quarter 2026 Financial Results

SAN DIEGO, July 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, announced today that it will report its financial results for the second quarter 2026 ended June 28, 2026, after the market closes on Thursday, August 6, 2026. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m.

Jul 24, 2026 03:00 AM • prnewswire.com
Beyond Fentanyl: How the Drug Crisis Is Changing

Beyond Fentanyl: How the Drug Crisis Is Changing

SAN DIEGO, July 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 59 of its Science Bytes podcast examining how the drug overdose landscape continues to evolve and what laboratory and emergency department professionals need to know to support patient care. Based on new guidance from the Association for Diagnostics and Laboratory Medicine (ADLM), the episode explores the growing complexity of toxicology testing amid counterfeit medications, polysubstance use and emerging synthetic opioids.

Jul 23, 2026 05:21 AM • prnewswire.com
Kaskela Law Firm Announces Investigation of QuidelOrtho Corp. (QDEL) and Encourages Long-Term QDEL Shareholders with Investment Losses to Contact the Firm

Kaskela Law Firm Announces Investigation of QuidelOrtho Corp. (QDEL) and Encourages Long-Term QDEL Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/quidelortho-corp/ Recently a securities fraud complaint was filed against QuidelOrtho on behalf of certain investors who purchased shares of the company's stock between February 17, 2022 and April 1, 2024 (the “Wrongdoing Peri.

Jul 23, 2026 03:00 AM • businesswire.com
QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL)("QuidelOrtho"), a leading global provider of diagnostic solutions, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of restricted stock units ("RSUs") with respect to 356,555 shares of the Company's common stock (the "Inducement Grant") to Micah Young, the Company's Chief Financial Officer and principal financial officer. The Inducement Grant was granted pursuant to the Company's 2026 Inducement Plan and as an inducement material to Mr.

Jul 15, 2026 03:31 PM • prnewswire.com

Price Targets